← Back to Search

Electrical Continence Device

Monitoring during activation of the FemPulse System for Overactive Bladder

N/A
Waitlist Available
Research Sponsored by FemPulse Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 hours
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this feasibility clinical investigation is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.

Eligible Conditions
  • Overactive Bladder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Autonomic nervous system response
Evoked Potential response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Monitoring during activation of the FemPulse SystemExperimental Treatment1 Intervention
Subjects will undergo non-invasive monitoring during activation of the FemPulse System.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
The FemPulse System
2019
N/A
~10

Find a Location

Who is running the clinical trial?

FemPulse CorporationLead Sponsor
3 Previous Clinical Trials
56 Total Patients Enrolled
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top